Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 405

1.

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial.

Shanafelt TD, Wang V, Kay NE, Hanson CA, O'Brien SM, Barrientos JC, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre S, Barr PM, Cashen AF, Mato AR, Singh A, Mullane MP, Little RF, Erba HP, Stone RM, Litzow M, Tallman MS.

Blood. 2019 Nov 13;134(Supplement_1):33. doi: 10.1182/blood-2019-126824.

PMID:
31723996
2.

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M.

N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.

PMID:
31365801
3.

Typical angina in a patient with Takayasu arteritis.

Hanson CA, Ragosta M.

Catheter Cardiovasc Interv. 2019 Jul 31. doi: 10.1002/ccd.28418. [Epub ahead of print]

PMID:
31364802
4.

Functional and Anatomical Imaging in Patients with Ischemic Symptoms and Known Coronary Artery Disease.

Hanson CA, Bourque JM.

Curr Cardiol Rep. 2019 Jul 1;21(8):79. doi: 10.1007/s11886-019-1155-3. Review.

PMID:
31264115
5.

Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies.

Tefferi A, Nicolosi M, Penna D, Vallapureddy R, Hanson CA, Pardanani A, Gangat N, Ketterling RP.

Leukemia. 2019 Oct;33(10):2522-2553. doi: 10.1038/s41375-019-0453-5. Epub 2019 May 1. No abstract available.

PMID:
31040370
6.

Historical Factors Associated With Past Environments Influence the Biogeography of Thermophilic Endospores in Arctic Marine Sediments.

Hanson CA, Müller AL, Loy A, Dona C, Appel R, Jørgensen BB, Hubert CRJ.

Front Microbiol. 2019 Feb 28;10:245. doi: 10.3389/fmicb.2019.00245. eCollection 2019.

7.

World Health Organization class-independent risk categorization in mastocytosis.

Pardanani A, Lasho TL, Reichard KK, Hanson CA, Tefferi A.

Blood Cancer J. 2019 Mar 4;9(3):29. doi: 10.1038/s41408-019-0189-5. No abstract available.

8.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

PMID:
30824279
9.

Nuclear cardio-oncology: From its foundation to its future.

Kahanda MG, Hanson CA, Patterson B, Bourque JM.

J Nucl Cardiol. 2019 Feb 20. doi: 10.1007/s12350-019-01655-6. [Epub ahead of print] Review.

PMID:
30788760
10.

Impact of an electronic decision support rule on ESR/CRP co-ordering rates in a community health system and projected impact in the tertiary care setting and a commercially insured population.

Juskewitch JE, Norgan AP, Johnson RD, Trivedi VA, Hanson CA, Block DR.

Clin Biochem. 2019 Apr;66:13-20. doi: 10.1016/j.clinbiochem.2019.01.009. Epub 2019 Jan 31.

PMID:
30711389
11.

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Vallapureddy RR, Mudireddy M, Penna D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Begna KH, Gangat N, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 25;9(2):12. doi: 10.1038/s41408-019-0175-y.

12.

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.

Gangat N, Phelps A, Lasho TL, Finke CM, Vallapureddy R, Hanson CA, Ketterling RP, Patnaik MM, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 24;9(2):11. doi: 10.1038/s41408-018-0167-3. No abstract available.

13.

Calculator-free point-of-care prognostication in myelodysplastic syndromes.

Tefferi A, Hanson CA, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2019 Apr;94(4):E99-E101. doi: 10.1002/ajh.25400. Epub 2019 Jan 24. No abstract available.

PMID:
30637785
14.

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.

Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA.

Am J Hematol. 2019 Mar;94(3):338-345. doi: 10.1002/ajh.25385. Epub 2019 Jan 8.

PMID:
30575108
15.

20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients.

Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2019 Mar;94(3):286-290. doi: 10.1002/ajh.25351. Epub 2018 Dec 5.

PMID:
30516867
16.

The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.

Tefferi A, Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Am J Hematol. 2019 Mar;94(3):299-305. doi: 10.1002/ajh.25349. Epub 2018 Dec 5.

PMID:
30516848
17.

MPL-mutated essential thrombocythemia: a morphologic reappraisal.

Szuber N, Hanson CA, Lasho TL, Finke C, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 20;8(12):121. doi: 10.1038/s41408-018-0159-3. No abstract available.

18.

Genetic predictors of response to specific drugs in primary myelofibrosis.

Penna D, Szuber N, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):120. doi: 10.1038/s41408-018-0158-4. No abstract available.

19.

Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates.

Szuber N, Lavu S, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):118. doi: 10.1038/s41408-018-0157-5. No abstract available.

20.

Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients.

Fan N, Lavu S, Hanson CA, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):119. doi: 10.1038/s41408-018-0156-6. No abstract available.

21.

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.

Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A.

Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245.

22.

Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis.

Szuber N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Leukemia. 2019 Mar;33(3):780-785. doi: 10.1038/s41375-018-0283-x. Epub 2018 Oct 12. No abstract available.

PMID:
30315236
23.

Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis.

Tefferi A, Shah S, Reichard KK, Hanson CA, Pardanani A.

Am J Hematol. 2019 Jan;94(1):E1-E2. doi: 10.1002/ajh.25302. Epub 2018 Nov 9. No abstract available.

PMID:
30281840
24.

Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.

Tefferi A, Szuber N, Vallapureddy RR, Begna KH, Patnaik MM, Elliott MA, Christopher Hook C, Wolanskyj AP, Hanson CA, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2019 Jan;94(1):5-9. doi: 10.1002/ajh.25294. Epub 2018 Oct 17.

PMID:
30252953
25.

A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status.

Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 Dec;93(12):E401-E404. doi: 10.1002/ajh.25290. Epub 2018 Oct 17. No abstract available.

PMID:
30230610
26.

Bone Marrow Biopsy Operator Experience and Impact on Aspirate, Biopsy, and Ancillary Testing Quality.

Marinelli LM, Fang H, Howard MT, Hanson CA, Haack JJ, Eick EA, Allen RJ, Ruffridge DE, Byrne CM, King RL.

Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 1;2(3):241-247. doi: 10.1016/j.mayocpiqo.2018.06.007. eCollection 2018 Sep.

27.

Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.

Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Dec;93(12):1474-1484. doi: 10.1002/ajh.25270. Epub 2018 Sep 27.

PMID:
30157297
28.

Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm.

Tefferi A, Shah S, Lasho TL, Patnaik MM, Reichard KK, Hanson CA, Ketterling RP, Pardanani A.

Am J Hematol. 2018 Dec;93(12):E383-E386. doi: 10.1002/ajh.25269. Epub 2018 Oct 17. No abstract available.

PMID:
30156701
29.

Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases.

Shah S, Pardanani A, Elala YC, Lasho TL, Patnaik MM, Reichard KK, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 Dec;93(12):1461-1466. doi: 10.1002/ajh.25265. Epub 2018 Sep 26.

PMID:
30152525
30.

Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA.

Br J Haematol. 2018 Nov;183(3):421-427. doi: 10.1111/bjh.15545. Epub 2018 Aug 16.

31.

Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels.

Tefferi A, Nicolosi M, Penna D, Mudireddy M, Szuber N, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani AD.

Blood Adv. 2018 Aug 14;2(15):1980-1984. doi: 10.1182/bloodadvances.2018018051. No abstract available.

32.

A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience.

Fang H, Ketterling RP, Hanson CA, Pardanani A, Kurtin PJ, Chen D, Greipp PT, Howard MT, King RL, Van Dyke DL, Reichard KK.

Am J Clin Pathol. 2018 Oct 1;150(5):421-431. doi: 10.1093/ajcp/aqy064.

PMID:
30032299
33.

Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts.

Mangaonkar AA, Gangat N, Al-Kali A, Elliott MA, Begna KH, Hanson CA, Ketterling RP, Wolanskyj-Spinner AP, Hogan WJ, Litzow MR, Patnaik MM.

Leuk Res. 2018 Aug;71:60-62. doi: 10.1016/j.leukres.2018.07.010. Epub 2018 Jul 11.

PMID:
30015104
34.

Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis.

Mudireddy M, Gangat N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Ashrani AA, Pardanani A, Nagorney DM, Tefferi A.

Am J Hematol. 2018 Sep;93(9):E235-E238. doi: 10.1002/ajh.25203. Epub 2018 Aug 31. No abstract available.

35.

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis.

Mudireddy M, Gangat N, Hanson CA, Ketterling RP, Pardanani A, Tefferi A.

Blood Cancer J. 2018 Jun 11;8(6):57. doi: 10.1038/s41408-018-0095-2. No abstract available.

36.

Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.

Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA.

Mayo Clin Proc. 2018 Oct;93(10):1363-1374. doi: 10.1016/j.mayocp.2018.04.013. Epub 2018 Jun 14.

PMID:
29866419
37.

PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.

He R, Ding W, Viswanatha DS, Chen D, Shi M, Van Dyke D, Tian S, Dao LN, Parikh SA, Shanafelt TD, Call TG, Ansell SM, Leis JF, Mai M, Hanson CA, Rech KL.

Am J Surg Pathol. 2018 Jul;42(7):843-854. doi: 10.1097/PAS.0000000000001077.

PMID:
29762141
38.

Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.

Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G.

Leukemia. 2018 Nov;32(11):2512-2518. doi: 10.1038/s41375-018-0143-8. Epub 2018 Apr 25. No abstract available.

39.

A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.

Patnaik MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, Hanson CA, Gangat N, Tefferi A, Pardanani A.

Leukemia. 2018 Aug;32(8):1850-1856. doi: 10.1038/s41375-018-0121-1. Epub 2018 Apr 2. No abstract available.

PMID:
29712989
40.

The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes.

Penna D, Nicolosi M, Vallapureddy RR, Szuber N, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Jul;93(7):E164-E167. doi: 10.1002/ajh.25114. Epub 2018 May 6. No abstract available.

41.

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM.

Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.

42.

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients.

Nicolosi M, Mudireddy M, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A, Tefferi A.

Leukemia. 2018 May;32(5):1254-1258. doi: 10.1038/s41375-018-0028-x. Epub 2018 Jan 30. No abstract available.

43.

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.

Tefferi A, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Leukemia. 2018 Oct;32(10):2274-2278. doi: 10.1038/s41375-018-0078-0. Epub 2018 Feb 27. No abstract available.

44.

U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates.

Tefferi A, Mudireddy M, Finke CM, Nicolosi M, Lasho TL, Hanson CA, Patnaik MM, Pardanani A, Gangat N.

Am J Hematol. 2018 Jun;93(6):E146-E148. doi: 10.1002/ajh.25084. Epub 2018 Apr 6. No abstract available.

45.

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Blood Cancer J. 2018 Mar 7;8(3):29. doi: 10.1038/s41408-018-0067-6.

46.

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.

Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, Hanson CA, Ketterling RP, Pardanani A.

Leukemia. 2018 May;32(5):1189-1199. doi: 10.1038/s41375-018-0018-z. Epub 2018 Feb 2.

47.

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.

Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A.

Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875.

48.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

49.

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.

Szuber N, Finke CM, Lasho TL, Elliott MA, Hanson CA, Pardanani A, Tefferi A.

Blood Cancer J. 2018 Feb 15;8(2):21. doi: 10.1038/s41408-018-0058-7. No abstract available.

50.

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts.

Mangaonkar AA, Lasho TL, Finke CM, Gangat N, Al-Kali A, Elliott MA, Begna KH, Alkhateeb H, Wolanskyj-Spinner AP, Hanson CA, Ketterling RP, Hogan WJ, Pardanani A, Litzow MR, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Feb 12;8(2):18. doi: 10.1038/s41408-018-0051-1. No abstract available.

Supplemental Content

Loading ...
Support Center